Early stimulation of acidification rate by novel cytotoxic pyridyl cyanoguanidines in human tumor cells: Comparison with m-iodobenzylguanidine

Biochemical Pharmacology

Volumn 60, Issue 6, 2000, Pages 839-849

  Ekelund, Sara ^a   Liminga, Gunnar ^a   Björkling, Fredrik ^b   Ottosen, Erik ^b   Schou, Charlotte ^b   Binderup, Lise ^b   Larsson, Rolf ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b LEO PHARMA A S   (Denmark)

Author keywords

Cyanoguanidine; Cytotoxicity; Extracellular acidification; Microphysiometry

Indexed keywords

(3 IODOBENZYL)GUANIDINE; GUANIDINE DERIVATIVE; N [6 (4 CHLOROPHENOXY)HEXYL] N' CYANO N'' 4 PYRIDYLGUANIDINE; UNCLASSIFIED DRUG;

ACIDIFICATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG STABILITY; DRUG SYNTHESIS; GLYCOLYSIS; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; LYMPHOMA; MITOCHONDRIAL RESPIRATION; MYELOMA CELL; PRIORITY JOURNAL; TUMOR CELL LINE;

3-IODOBENZYLGUANIDINE; ANTINEOPLASTIC AGENTS; CYANIDES; DNA, NEOPLASM; FLUOROMETRY; GUANIDINES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; NEOPLASM PROTEINS; TUMOR CELLS, CULTURED;

EID: 0034666688     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00382-8     Document Type: Article

References (31)

1. Schou C., Ottosen E.R., Petersen H.J., Björkling F., Latini S., Hjarnaa P.V., Bramm E., Binderup L. Novel cyanoguanidines with potent oral antitumour activity. Bioorg Med Chem Lett. 7:1997;3095-3100.
2. Petersen H.J., Kaegaard Nielsen C., Arrigoni-Martelli E. Synthesis and hypotensive activity of N-alkyl-N″-cyano-N′-pyridylguanidines. J Med Chem. 21:1978;773-781.
3. Vig Hjarnaa P.-J., Dhar S., Latini S., Jonsson E., Larsson R., Bramm E., Skov T., Binderup L. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. Cancer Res. 59:1999;5751-5757.
4. Smets L.A., Bout B., Wisse J. Cytotoxic and antitumor effects of the norepinephrine analogue meta-iodo-benzylguanidine (MIBG). Cancer Chemother Pharmacol. 21:1988;9-13.
5. Sisson J.C., Frager M.S., Valk T.W., Gross M.D., Swanson D.P., Wieland D.M., Tobes M.C., Beierwaltes W.H., Thompson N.W. Scintigraphic localization of pheochromocytoma. N Engl J Med. 305:1981;12-17.
6. Sisson J.C., Shapiro B., Beierwaltes W.H., Glowniak J.V., Nakajo M., Mangner T.J., Carey J.E., Swanson D.P., Copp J.E., Satterlee W.G., Wieland D.M. Radiopharmaceutical treatment of malignant pheochromocytoma. J Nucl Med. 24:1984;197-206.
7. Loesberg C., Van Rooij H., Nooijen W.J., Meijer A.J., Smets L.A. Impaired mitochondrial respiration and stimulated glycolysis by m-iodobenzylguanidine (MIBG). Int J Cancer. 46:1990;276-281.
8. Cornelissen J., Wanders R.J., Van den Bogert C., Van Kuilenburg A.B., Elzinga L., Voute P.A., Van Gennip A.H. Meta-iodobenzylguanidine (MIBG) inhibits malate and succinate driven mitochondrial ATP synthesis in the human neuroblastoma cell line SK-N-BE(2c). Eur J Cancer. 31A:1995;582-586.
9. Sundström C., Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer. 17:1976;565-577.
10. Larsson R., Kristensen J., Sandberg C., Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer. 50:1992;177-185.
11. Nygren P., Fridborg H., Csoka K., Sundström C., De La Torre M., Kristensen J., Bergh J., Hagberg H., Glimelius B., Rastad J., Tholander B., Larsson R. Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. Int J Cancer. 56:1994;715-720.
12. Owicki J.C., Parce J.W. Biosensors based on the energy metabolism of living cells The physical chemistry and cell biology of extracellular acidification . Biosens Bioelectron. 7:1992;255-272.
13. McConnell H.M., Owicki J.C., Parce J.W., Miller D.L., Baxter G.T., Wada H.G., Pitchford S. The Cytosensor microphysiometer Biological applications of silicon technology . Science. 257:1992;1906-1912.
14. Owicki J.C., Bousse L.J., Hafeman D.G., Kirk G.L., Olson J.D., Wada H.G., Parce J.W. The light-addressable potentiometric sensor Principles and biological applications . Annu Rev Biophys Biomol Struct. 23:1994;87-113.
15. Hafeman D.G., Parce J.W., McConnell H.M. Light-addressable potentiometric sensor for biochemical systems. Science. 240:1988;1182-1185.
16. Carson R., Nigerian P., Ekberg M., Slater L. Chemotherapeutic drug sensitivity testing of leukaemic cells in vitro using a semiautomated fluorometric assay. Leukemia. 4:1990;567-571.
17. Nygren P., Kristensen J., Jonsson B., Lönnerholm G., Kreuger A., Larsson R. Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphocytic leukemia. Leukemia. 6:1992;1121-1128.
18. Harris D.W., Kenrick M.K., Pither R.J., Anson J.G., Jones D.A. Development of a high-volume in situ mRNA hybridization assay for the quantification of gene expression utilizing scintillating microplates. Anal Biochem. 243:1996;249-256.
19. Graves R., Davies R., Brophy G., O'Beirne G., Cook N. Noninvasive, real-time method for the examination of thymidine uptake events Application of the method to V-79 cell synchrony studies . Anal Biochem. 248:1997;251-257.
20. Loesberg C., Van Rooij H., Romijn J.C., Smets L.A. Mitochondrial effects of the guanidino group-containing cytostatic drugs, m-iodobenzylguanidine and methylglyoxal bis (guanylhydrazone). Biochem Pharmacol. 42:1991;793-798.
21. Ekelund S., Nygren P., Larsson R. Microphysiometry New technology for evaluation of anticancer drug activity in human tumor cells in vitro . Anti-Cancer Drugs. 9:1998;531-538.
22. Åleskog A, Bashir-Hassan S, Jonsson E, Alvfors C, Kristensen J and Larsson R, In vitro activity of CHS 828 in primary cultures of human hematological and solid tumors. 90th Annual Meeting of the American Association for Cancer Research 40, p. 299. Cadmus Journal Services, Philadelphia, 1999.
23. Tannock I.F., Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 49:1989;4373-4384.
24. - exchange. Eur J Cancer. 29A:1992;132-137.
25. Rotin D., Wan P., Grinstein S., Tannock I. Cytotoxicity of compounds that interfere with the regulation of intracellular pH A potentially new class of anticancer drugs . Cancer Res. 47:1987;1497-1504.
26. Maidorn R.P. Jr, Cragoe E.J., Tannock I.F. Therapeutic potential of analogues of amiloride Inhibition of the regulation of intracellular pH as a possible mechanism of tumour selective therapy . Br J Cancer. 67:1993;297-303.
27. Kuin A., Aalders M., Lamfers M., van Zuidam D.J., Essers M., Beijnen J.H., Smets L.A. Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG). Br J Cancer. 79:1999;793-801.
28. + exchange inhibition induces intracellular acidosis and differentially impairs cell growth and viability of human and rat hepatocarcinoma cells. Toxicol Lett. 106:1999;215-228.
29. Sakamoto N., Toge T., Nishiyama M. Tumor-specific synergistic therapy of mitomycin C Modulation of bioreductive activation . Hiroshima J Med Sci. 46:1997;67-73.
30. Cummings J., Spanswick V., Tomasz M., Smyth J.F. Enzymology of mitomycin C metabolic activation in tumour tissue. Biochem Pharmacol. 56:1998;405-414.
31. Wike-Hooley J.L., Haveman J., Reinhold H.S. The relevance of tumour pH to the treatment of malignant disease. Radiother Oncol. 2:1984;343-366.